2
Clinical Trials associated with IDN-5243Tolerability, Safety and Activity of IDN5243, 4 mg Bid Intramuscularly in the Treatment of Low Back Pain. A Prospective, Open Label, Single-center, Uncontrolled Study
This is a prospective cohort study, open-label, uncontrolled proof of concept trial. The trial objective is to evaluate the analgesic tolerability, safety and activity of IDN 5243 (3-glycosyl-3-O-demethylthiocolchicine derivative)administered intramuscularly at 4 mg b.i.d. for 5 days in the morning (8.00-10.00 AM) and in the evening (6.00-8.00 PM) in subjects with Low Back Pain (LBP).
/ Not yet recruitingPhase 2 Tolerability, safety and activity of IDN5243, 4 mg bid intramuscularly in the treatment of low back pain. A prospective, open label, single-center, uncontrolled study. - IDN 5243 in LBP
Start Date25 Aug 2015 |
Sponsor / Collaborator- |
100 Clinical Results associated with IDN-5243
100 Translational Medicine associated with IDN-5243
100 Patents (Medical) associated with IDN-5243
100 Deals associated with IDN-5243